Laurent Peyrin-Biroulet1, Gert Van Assche2, Andreas Sturm3, Javier P Gisbert4, Daniel R Gaya5, Bern Bokemeyer6, Gerassimos J Mantzaris7, Alessandro Armuzzi8, Shaji Sebastian9, Nuria Lara10, Mark Lynam10, Sonia Rojas-Farreras10, Tao Fan11, Qian Ding11, Christopher M Black11, Sumesh Kachroo11. 1. Department of Hepato-Gastroenterology and Inserm U954, University Hospital of Nancy, Lorraine University, Vandoeuvre-lès-Nancy, France. Electronic address: peyrinbiroulet@gmail.com. 2. Division of Gastroenterology, University Hospitals Leuven, Leuven Belgium. 3. Department of Gastroenterology, DRK Kliniken Berlin I Westend, Berlin, Germany. 4. Gastroenterology Unit, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-IP) and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain. 5. Gastroenterology Unit, Glasgow Royal Infirmary, Glasgow, United Kingdom. 6. Gastroenterology Practice, Minden, Germany. 7. Department of Gastroenterology, Evangelismos Hospital, Athens, Greece. 8. IBD Unit, Complesso Integrato Columbus, Catholic University, Rome, Italy. 9. Gastroenterology and IBD Unit, Hull and East Yorkshire Hospitals NHS Trust, Hull, United Kingdom. 10. IMS Health, Real World Evidence Solutions, Spain. 11. Merck & Co., Inc., Kenilworth, NJ, United States.
Abstract
BACKGROUND: Ulcerative colitis (UC) is a life time disease and issues with therapy may impact on patient satisfaction and treatment preferences. AIMS: To assess disease and treatment perception gaps from patients' and physicians' perspectives in UC patients. METHODS: Adult patients with moderate-to-severe UC (Mayo score ≥6) naïve to biologic therapy were enrolled in a European, observational, cross-sectional, retrospective study. Treatment satisfaction was assessed by the TSQM questionnaire and treatment preferences and patient's knowledge with pre-defined questions. Physicians' and patients' perceptions were compared through the level of agreement. RESULTS: 256 patients from 11 European countries were included. 48.0% of patients were dissatisfied with their current treatment. Effectiveness, long lasting action, rapid start of action, and fewer side effects were the attributes more frequently considered important or very important by patients (96.9%, 89.1%, 83.8%, and 81.8%, respectively). 26.2% patients rated their overall disease knowledge as very knowledgeable. The agreement between patients' and physicians on disease severity was good (kappa=0.62). CONCLUSION: Half patients with moderate-to-severe UC managed with conventional therapy, are dissatisfied with their treatments. Effectiveness, long lasting action and rapidity of action were the most frequently rated items in treatment preferences. There are major gaps between physicians and patients when evaluating disease burden.
BACKGROUND:Ulcerative colitis (UC) is a life time disease and issues with therapy may impact on patient satisfaction and treatment preferences. AIMS: To assess disease and treatment perception gaps from patients' and physicians' perspectives in UC patients. METHODS: Adult patients with moderate-to-severe UC (Mayo score ≥6) naïve to biologic therapy were enrolled in a European, observational, cross-sectional, retrospective study. Treatment satisfaction was assessed by the TSQM questionnaire and treatment preferences and patient's knowledge with pre-defined questions. Physicians' and patients' perceptions were compared through the level of agreement. RESULTS: 256 patients from 11 European countries were included. 48.0% of patients were dissatisfied with their current treatment. Effectiveness, long lasting action, rapid start of action, and fewer side effects were the attributes more frequently considered important or very important by patients (96.9%, 89.1%, 83.8%, and 81.8%, respectively). 26.2% patients rated their overall disease knowledge as very knowledgeable. The agreement between patients' and physicians on disease severity was good (kappa=0.62). CONCLUSION: Half patients with moderate-to-severe UC managed with conventional therapy, are dissatisfied with their treatments. Effectiveness, long lasting action and rapidity of action were the most frequently rated items in treatment preferences. There are major gaps between physicians and patients when evaluating disease burden.
Authors: Christopher Sj Probert; Shaji Sebastian; Daniel R Gaya; P John Hamlin; Gillian Gillespie; Anita Rose; Helen Tate; Colin Wheeler; Peter M Irving Journal: BMJ Open Gastroenterol Date: 2018-07-07
Authors: C Le Berre; A Bourreille; M Flamant; G Bouguen; L Siproudhis; M Dewitte; N Dib; E Cesbron-Metivier; T Goronflot; M Hanf; P-A Gourraud; E Kerdreux; A Poinas; C Trang-Poisson Journal: BMC Gastroenterol Date: 2020-04-16 Impact factor: 3.067